Patupilone (EPO906, Epothilone B)

製品コードS1364

Patupilone (EPO906, Epothilone B)化学構造

分子量(MW):507.68

Patupilone (EPO906, Epothilone B) は、一種のパクリタキセ(paclitaxel)のようなマイクロチューブ安定剤で、 EC0.01が1.8μM。臨床2期。

サイズ 価格(税別) 在庫  
JPY 41500.00 あり
JPY 11620.00 あり
JPY 19920.00 あり
JPY 34860.00 あり
JPY 78020.00 あり

カスタマーフィードバック(3)

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Patupilone (EPO906, Epothilone B) は、一種のパクリタキセ(paclitaxel)のようなマイクロチューブ安定剤で、 EC0.01が1.8μM。臨床2期。
ターゲット
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
体外試験

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell MnTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NI\hNW5KdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd5ZT2wOkDPxE1? NGTmc5FUSU6JRWK=
human A431 cell MlHNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nEXmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFZmNTB4IN88US=> NH7YZoRUSU6JRWK=
human SW1710 cell MnjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVRmNTB3IN88US=> MXvTRW5ITVJ?
human Daoy cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPFTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYpvwKwhUUN3ME2yMlc{\S1yNTFOwG0> NF\DNFdUSU6JRWK=
human BFTC-905 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFm4NJdKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OXWtNFUh|ryP M{nUOHNCVkeHUh?=
human A375 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUO3cldPUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OYUuODVizszN MV\TRW5ITVJ?
human RKO cell MoDIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnvO5RCUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ4\S1yNTFOwG0> NWXySZVDW0GQR1XS
human KYSE-510 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIT1dItKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|OHWtNFUh|ryP MkXmV2FPT0WU
human HLE cell MknUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwMk\lMVA2KM7:TR?= MWPTRW5ITVJ?
human MCF7 cell M4L4XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NY[2WYNXUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE43PmVvMEWg{txO MoPKV2FPT0WU
human 786-0 cell MoHvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNUBvVQ>? Mn33V2FPT0WU
human TE-8 cell Mo[xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7OTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVEhdk1? NF65cHZUSU6JRWK=
ovarian carcinoma 1A9 cell M1XYOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCxdnHybYFvKGOjcnPpco9u[SBzQUmgZ4VtdCCpcn;3eIg> NVL2d3FWOTZzM{S5Nlg>
human PANC-03-27 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{O1fGlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUOyJO69VQ>? Mli0V2FPT0WU
human VMRC-RCZ cell MnG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHiTY5pcWKrdHnvckBw\iCqdX3hckBXVVKFLWLDXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTN4IN88US=> MWDTRW5ITVJ?
human IGROV-1 cell MkHjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoC4TY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTZizszN MlLnV2FPT0WU
human MG-63 cell MmPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGjmd|lKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjVizszN M3XRbnNCVkeHUh?=
human SIG-M5 cell NIOxRlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn7nTY5pcWKrdHnvckBw\iCqdX3hckBUUUdvTUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE3QSEQvF2= MnnPV2FPT0WU
human NCI-H650 cell M4XENmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PSWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5IN88US=> M4L4VnNCVkeHUh?=
human PSN1 cell NFu5S41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzLTFFKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE4OyEQvF2= MnnvV2FPT0WU
human PA-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3OEDPxE1? NFL0SIdUSU6JRWK=
KB-8511 cells NHnwcVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{D5Z|czKGh? NF\GT|REd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgeIhmKGe{b4f0bEBw\iCyYXPsbZRigGWuLYLld4l{fGGwdDDoeY1idiCncHnk[ZJud2mmIHPhdoNqdm:vYTDj[YxteyCNQj24OVEyKGK7IEWwJJBmemOnboSgLFczKGi{IHX4dI9{fXKnKTygTWM2OD1yLkG4JO69VQ>? M2nmc|EyOTN|MEi2
KB-31 cells MlP2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmjpO|IhcA>? MkmzR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2|ZX7zbZRqfmViaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvM{GgZpkhPTBicHXyZ4VvfCBqN{KgbJIh\Xiyb4P1doUq NIXBXo0yOTF|M{C4Oi=>
human BHY cell NHPvbmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mk\sTY5pcWKrdHnvckBw\iCqdX3hckBDUFliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5OUBvVQ>? MnrqV2FPT0WU
human BB30-HNC cell MmHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2\NbmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> MoDjV2FPT0WU
human HOS cell M4\QeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\he4JKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE2KM7:TR?= MWPTRW5ITVJ?
human 639-V cell M3q2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHsTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE5KM7:TR?= NETv[WNUSU6JRWK=
human ES1 cell  M3nUN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1vaXWlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlEh|ryP M2DB[3NCVkeHUh?=
human TE-15 cell  NF\TWIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\B[2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPSEQvF2= MlHRV2FPT0WU
human LXF-289 cell NH:3WYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY[5TJQ3UW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{N{eg{txO MX\TRW5ITVJ?
human CAL-12T cell NUjVW3V[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QSEQvF2= M1fITHNCVkeHUh?=
human T84 cell NVr2TWx4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkH5TY5pcWKrdHnvckBw\iCqdX3hckBVQDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK0JO69VQ>? MnvJV2FPT0WU
human KYSE-450 cell MmruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEG2cZNKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO MnnHV2FPT0WU
human LCLC-103H cell NEe4U|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzFibl2= NHXoWnNUSU6JRWK=
human NCI-H810 cell NWLqWG5XT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3HNWtNUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{KyJO69VQ>? MUjTRW5ITVJ?
human HUTU-80 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQCEQvF2= NXXnPYtJW0GQR1XS
human NCI-H460 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkSzTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN|IN88US=> NEW0XGlUSU6JRWK=
human HGC-27 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M5KM7:TR?= NWLLTFZbW0GQR1XS
human HSC-2 cell NGXYeoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlMhdk1? NVrlbVYxW0GQR1XS
human IA-LM cell M4[1fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEH1XFJKdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTNizszN NEHqWohUSU6JRWK=
human HMV-II cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1TIO2lvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NHfKbm5USU6JRWK=
human COLO-679 cell MlHFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfiTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[3PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl2IN88US=> MlfTV2FPT0WU
human NCI-H2122 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUPEWmJ2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VQ>? NESxdnVUSU6JRWK=
human CAL-39 cell NGfL[WZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWD6W4lFUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzMTFOwG0> MYnTRW5ITVJ?
human SW954 cell Ml;1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60N|Yh|ryP MonnV2FPT0WU
human LCLC-97TM1 cell NYTP[YVwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlrvTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NESg{txO MnKxV2FPT0WU
human KYSE-270 cell NEjVNmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjBbWx5UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNES1JO69VQ>? NGToUXpUSU6JRWK=
human NB13 cell NFv2Ro9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEL4b29KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ1PyEQvF2= MUTTRW5ITVJ?
human SK-LMS-1 cell M2HLdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoL3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2OTWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR4IN88US=> M2LkfHNCVkeHUh?=
human SW620 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\3TY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOlQ5KM7:TR?= MlXJV2FPT0WU
human HCT-15 cell NV;4S5FVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLSZZpwUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjdzNzFOwG0> NHj0[ZNUSU6JRWK=
human DU-145 cell NFvkd5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTGTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= NYTlU2dZW0GQR1XS
human ST486 cell NIDTdHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIXIeJNKdmirYnn0bY9vKG:oIHj1cYFvKFOWNEi2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjFizszN M3nUSXNCVkeHUh?=
human A427 cell M3XaWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnTTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64Nlgh|ryP Mnu4V2FPT0WU
human HT-1080 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGS0OGpKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2MjFOwG0> M{jLTXNCVkeHUh?=
human NCI-H2009 cell NFfUSndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjPV4pKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlAxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOE[yJO69VQ>? MVHTRW5ITVJ?
human SK-LU-1 cell Mlf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoSzTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjZizszN M3LW[3NCVkeHUh?=
human SCC-4 cell NGfyZo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64O|ch|ryP M3O0[XNCVkeHUh?=
human NCI-H1299 cell NEfGXIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2Cy[mlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56ODFOwG0> NI\FfIFUSU6JRWK=
human NH-12 cell MkixS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVzJcohq[mm2aX;uJI9nKGi3bXHuJG5JNTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64PVEh|ryP NX\rU3BVW0GQR1XS
human SK-UT-1 cell M3PBSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFSzcIVKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh7MjFOwG0> Mn7wV2FPT0WU
human Bel7402 MlrDVJJwdGmoZYLheIlwdiCjc4PhfS=> M{\vUlczKGh? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUC9NE46KM7:TR?= NWLyTYdQOjJ|MkCzOVQ>
human A388 cell NIryVlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPlN2ZKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1KM7:TR?= NULBUmZ[W0GQR1XS
human SW982 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnMVnhwUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTl7IN88US=> MnHZV2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
細胞試験: [2]
+ 展開
  • 細胞株: KB3-1, KBV-1, Hela, and Hs578T cells
  • 濃度: 0–1 μM
  • 反応時間: 72 hours
  • 実験の流れ: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Mice xenograft model of RPMI 8226 cells
  • 製剤: Dissolved in30% PEG-300
  • 投薬量: 2.5 mg/kg–4 mg/kg
  • 投与方法: Inject intravenously
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 507.68
化学式

C27H41NO6S

CAS No. 152044-54-7
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Patupilone (EPO906, Epothilone B)を買う | Patupilone (EPO906, Epothilone B) ic50 | Patupilone (EPO906, Epothilone B)供給者 | Patupilone (EPO906, Epothilone B)を購入する | Patupilone (EPO906, Epothilone B)費用 | Patupilone (EPO906, Epothilone B)生産者 | オーダーPatupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B)化学構造 | Patupilone (EPO906, Epothilone B)分子量 | Patupilone (EPO906, Epothilone B)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID